Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or <u>Fax</u> (703) 746-4000

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

20999

7590

12/30/2004

FROMMER LAWRENCE & HAUG 745 FIFTH AVENUE- 10TH FL. NEW YORK, NY 10151

04/05/2005 HTECKLU2 00000064 09698903

01 FC:1501

1400.00 OP



Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the WSPTO (703) 746-4000, on the date indicated below

transmitted	to the ge	13 F TO (103) 1-	+0-4000, on me	uate ii	idicated below.
WiA 7 i a	am /F/	Lawren	re Rea	28	029 (Depositor's name)
SIU	71				(Signature)
March	30,	2005			(Date)
				T	

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/698 903	10/27/2000	Brigitte Weston	514412-2020.1	8217

TITLE OF INVENTION: METHODS FOR DETERMINING THE PRESENCE OR ABSENCE OF ELITE EVENT MS-B2 IN BRASSICA PLANT MATERIAL

CFR 1.363).  Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.  The Address indication (or "Fee Address" Indication form PTO/SB/147; Rev 03-02 or more recent) attached. Use of a Customer Number is required.  ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)  PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filter recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.  (A) NAME OF ASSIGNEE  (B) RESIDENCE: (CITY and STATE OR COUNTRY)  Bayer BioScience N.V  Gent, Belgium  Please check the appropriate assignee category or categories (will not be printed on the patent):  Ab Payment of Fee(s):  A check in the amount of the fee(s) is enclosed.  Payment by credit card. Form PTO-2038 is attached.  A dvance Order - # of Copies3  A check in the amount of the fee(s) is enclosed.  Payment by credit card. Form PTO-2038 is attached.  A check in the amount of the fee(s) or credit any overpaymen Deposit Account Number 50 0320 (enclose an extra copy of this form).  5. Change in Entity Status (from status indicated above)  A applicant claims SMALL ENTITY status. See 37 CFR 1.27.	APPLN. TYPE	APPLN. TYPE SMALL ENTITY		EE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
KUBELIK, ANNER  1638  800-006000  1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).  1. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.  1. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.  1. The Address indication (or "Fee Address" Indication form PTO/SB/122) attached.  1. The Address indication (or "Fee Address" Indication form PTO/SB/122) attached. Use of a Customer Number is required.  3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)  PLEASE NOTE: Unless an assignce is identified below, no assignee data will appear on the patent. If an assignce is identified below, the document has been filed recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.  (A) NAME OF ASSIGNEE  (B) RESIDENCE: (CITY and STATE OR COUNTRY)  Bayer BioScience N.V  Gent, Belgium  Please check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Government of the Ce(s) is enclosed.  1. Payment of Fee(s): A check in the amount of the fee(s) is enclosed.  1. Payment of Fee(s): A check in the amount of the fee(s) is enclosed.  1. Payment by credit card. Form PTO-2038 is attached.  2. Advance Order - # of Copies 3  3. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  3. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  3. D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27.  3. Applicant claims SMALL ENTITY status fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if Proquired) will not be accepted from anyone other than the applicant; a registered attorney or agent, or the assignce or other part interest as shown by the records of the United Spates Patent and Trademark Office.	nonprovisional	nonprovisional NO		ı	\$0	\$1400	03/30/2005
1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.563).    Change of correspondence address (or Change of Correspondence Address form PTO/SB/12;) attached.   The Address' indication for "Fee Address' indication for "Fee Address' indication for "Fee Address' indication for "Fee Address' Indication for "PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.    Assigne Name And Residence address indication for "Fee Address' Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.    Assigne Name And Residence address indication for "Fee Address' Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.    Assigne Name And Residence address indication for "Fee Address' Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.    Assigne Name And Residence address indication form pto Name Indication as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment in the printed on the patent. If an assignee is identified below, the document has been filed recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment in the printed on the patent in the printed on the patent in the patent in the printed on the patent in the printed on the patent in the printed on the patent in the patent in the printed on the patent in the patent in the printed in the patent in the printed on the patent in the patent in the printed in the printed on the patent in the patent in the printed in the patent in the printed in the printed on the patent in the patent in the patent in the printed in the printed in the printed in the patent in the	EXAMINER		ART UNIT		CLASS-SUBCLASS	Ì	
CFR 1.363).  (1) the names of up to 3 registered patent attorneys or agents OR, alternatively.  (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered attorney or agent) and the names of up to 2 registered attorney or agents. If no name is listed, no name will be printed.  3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)  PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filter recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.  (A) NAME OF ASSIGNEE  (B) RESIDENCE: (CITY and STATE OR COUNTRY)  Bayer BioScience N.V  Gent, Belgium  Please check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Government of Fee(s):  Advance Order - # of Copies3  3. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if raquired) will not be accepted from anyone other than the applicant; a registered attorney or agent) and the names of up to 3 registered patent attorneys or agents. If no name is 1.27 is 1.27 is 2.2 is 4.4	KUBELII	1638		800-006000	•		
Bayer BioScience N.V  Gent, Belgium  Please check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Government of the fee(s) are enclosed:  4b. Payment of Fee(s):  A check in the amount of the fee(s) is enclosed.  Payment by credit card. Form PTO-2038 is attached.  Advance Order - # of Copies3  The Director is hereby authorized by charge the required fee(s), or credit any overpayment of peposit Account Number 50 0320 (enclose an extra copy of this form).  5. Change in Entity Status (from status indicated above)  a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other part interest as shown by the records of the United States Patent and Trademark Office.	CFR 1.363).  Change of corresponded ress form PTO/SB/1  "Fee Address" indication PTO/SB/47; Rev 03-02  Number is required.  3. ASSIGNEE NAME ANI  PLEASE NOTE: Unless	dence address (or Change of 22) attached.  tion (or "Fee Address" Indicator more recent) attached. Use D RESIDENCE DATA TO Be an assignee is identified be	Correspondence  ation form  of a Customer  E PRINTED ON T	(1) the na or agents (2) the na registered 2 registere listed, no HE PATEN data will app	mes of up to 3 registered pater OR, alternatively, me of a single firm (having as a attorney or agent) and the named patent attorneys or agents. If name will be printed.  T (print or type)	a member a les of up to no name is 3	& Haug LLP
4a. The following fee(s) are enclosed:    Ab. Payment of Fee(s):   X   Issue Fee	Bayer BioSc	ience N.V	. ,	Gent,	Belgium	ŕ	roun entity 🔲 Governme:
Advance Order - # of Copies 3 The Director is hereby authorized by charge the required fee(s), or credit any overpaymen Deposit Account Number 50 0320 (enclose an extra copy of this form).  5. Change in Entity Status (from status indicated above)  a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).  The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other part interest as shown by the records of the United States Patent and Trademark Office.	4a. The following fee(s) are	enclosed:	4b.	Payment of A check	Fee(s): in the amount of the fee(s) is en	closed.	
5. Change in Entity Status (from status indicated above)  a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).  The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other particles as shown by the records of the United States Patent and Trademark Office.	_ `	•	•	•	•		r credit any overpayment, copy of this form).
£1. 1//1.0.0	a. Applicant claims S	MALL ENTITY status. See	) 37 CFR 1.27.	b. Applic	cant is no longer claiming SMAI	LL ENTITY status. See 37 (	CFR 1.27(g)(2).
£1. 1//1.0.0	The Director of the USPTO NOTE: The Issue Fee and P interest as shown by the rec	is requested to apply the Issu Publication Fee (if required) vords of the United States Pate	e Fee and Publicate vill not be accepted ent and Trademark	ion Fee (if and from anyon of Office.	ny) or to re-apply any previously e other than the applicant; a regi	y paid issue fee to the applic stered attorney or agent; or	ration identified above. the assignee or other party
Typed or printed name William F. Tawrence Registration No. 28,029	Authorized Signature	Que Ille	eep		Date <u>Ma</u>	rch 30, 2005	

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to emplete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTOL-85 (Rev. 12/04) Approved for use through 04/30/2007.

04/05/2005 HTECKLU2 00000065 500320 09698903

01 FC:8001

9.00 DA

OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE